paclitaxel

Type: Keyphrase
Name: paclitaxel
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Sorrento Announces the Unexpected Death of its Chief Business Officer

SAN DIEGO"Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Amar's family and friends," said Henry JiMr. Singh joined Sorrento in January 2014About Sorrento Therapeutics, Inc.Sorrento is ... [Published Benzinga.com - 7 hours ago]
First reported Jul 31 2014 - Updated 18 hours ago - 2 reports

Boston Scientific receives CE mark for paclitaxel-coated PTCA balloon catheter

Boston Scientific Corporation, a developer, manufacturer and marketer of medical devices, has received CE mark and has begun the European market launch of the Agent paclitaxel-coated PTCA balloon catheter. The Agent Drug-Coated Balloon (DCB) provides ... [Published Individual.com - 18 hours ago]
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Researchers at University of North Carolina Describe Findings in Breast Cancer (2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for...

Researchers at University of North Carolina Describe Findings in Breast Cancer (2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer)By a News Reporter-Staff News Editor at Cancer Weekly -- Current ... [Published HispanicBusiness.com - 21 hours ago]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Patent Issued for Drug Delivery by Carbon Nanotube Arrays

By a News Reporter-Staff News Editor at Biotech Week -- A patent by the inventors Gharib, Morteza ( Altadena, CA ); Aria, Adrianus Indrat ( Pasadena, CA ); Beizai, Masoud ( Laguna Hills, CA ), filed on September 1, 2011 , was published online on July ... [Published HispanicBusiness.com - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 2 reports

Reports on Doxorubicin Therapy Findings from Chinese Academy of Sciences Provide New Insights (A co-delivery system based on paclitaxel grafted...

Reports on Doxorubicin Therapy Findings from Chinese Academy of Sciences Provide New Insights (A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: Preparation, in vitro and in vivo evaluation) By a News Reporter-Staff ... [Published Street Sweeper - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 2 reports

New Paclitaxel Therapy Study Findings Have Been Reported by J.K. Lu and Co-Researchers (Free paclitaxel loaded PEGylated-paclitaxel nanoparticles:...

New Paclitaxel Therapy Study Findings Have Been Reported by J.K. Lu and Co-Researchers (Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: Preparation and comparison with other paclitaxel systems in vitro and in vivo) By a News Reporter-Staff ... [Published Crawford Financial Planning - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Investigators from University of Texas Report New Data on Paclitaxel Therapy (Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances...

Investigators from University of Texas Report New Data on Paclitaxel Therapy (Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway)By a News Reporter-Staff News Editor at Clinical Trials ... [Published HispanicBusiness.com - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Biomineralized Anisotropic Gold Microplate–Macrophage Interactions Reveal Frustrated Phagocytosis-like Phenomenon: A Novel Paclitaxel Drug Delivery Vehicle

ACS Applied Materials & Interfaces DOI: 10.1021/am5 ... [Published ACS Applied Materials & Interfaces - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Boston Scientific receives CE mark for agent drug-coated balloon

-- Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market launch of the Agent Paclitaxel-Coated PTCA Balloon Catheter. ... [Published Cardiovascular Business - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Boston Scientific Receives CE Mark For Ranger? Drug-Coated Balloon

By a News Reporter-Staff News Editor at Biotech Business Week Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger? ... [Published Pharmacy Choice - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Nanotax trail shows promise in treating abdominal cancers

A repurposed drug originally used to treat ovarian cancer saw positive results for patients with advanced peritoneal cancers during a phase I clinical trial at The University of Kansas Cancer Center.The drug, known under the brand name Nanotax, is a fine ... [Published Noodls - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Genentech's ovarian cancer drug receives FDA acceptance for priority review

Genentech Inc., a biotechnology company, has announced the FDA acceptance and priority review for the company's supplemental biologics license application, or sBLA, of Avastin plus chemotherapy for the treatment of women with persistent, recurrent platinum-resistant ... [Published Individual.com - Jul 25 2014]

Quotes

"Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Amar's family and friends" said Henry Ji , Ph D , Sorrento's President and Chief Executive Officer
...best treatment options for patients with coronary artery disease," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "We believe the addition of a highly-differentiated DCB to our leading complex percutaneous coronary intervention portfolio strengthens the Boston Scientific position as a global innovator in interventional cardiology therapies."
According to the news editors, the research concluded: "These benefits resulted in significantly improved antitumor efficacy with the NP-based formulation."
"The invention disclosed herein enables improved devices, methods and compositions for treating a number of conditions where targeted, localized, and controlled drug delivery are required."

More Content

All (266) | News (238) | Reports (0) | Blogs (20) | Audio/Video (0) | Fact Sheets (4) | Press Releases (3)
sort by: Date | Relevance
Exelixis' (EXEL) CEO Michael Morrissey on Q2 20... [Published Seeking Alpha - 1 hour ago]
Sorrento Announces the Unexpected Death of its ... [Published TVNewsCheck - 7 hours ago]
Sorrento Announces the Unexpected Death of its ... [Published Benzinga.com - 7 hours ago]
Pfizer, Merck Focusing On Nanomedicine As Next ... [Published Bidness Etc - 13 hours ago]
Boston Scientific receives CE mark for paclitax... [Published Individual.com - 18 hours ago]
Researchers at University of North Carolina Des... [Published HispanicBusiness.com - 21 hours ago]
Reports on Doxorubicin Therapy Findings from Ch... [Published Street Sweeper - Jul 31 2014]
Reports on Doxorubicin Therapy Findings from Ch... [Published Industrial Info Financials - Jul 31 2014]
New Paclitaxel Therapy Study Findings Have Been... [Published Crawford Financial Planning - Jul 31 2014]
Patent Issued for Drug Delivery by Carbon Nanot... [Published HispanicBusiness.com - Jul 31 2014]
New Paclitaxel Therapy Study Findings Have Been... [Published HispanicBusiness.com - Jul 31 2014]
BIOSENSORS : Researchers Submit Patent Applicat... [Published 4 Traders - Jul 31 2014]
BOSTON SCIENTIFIC : Receives CE Mark For Agent™... [Published 4 Traders - Jul 31 2014]
Investigators from University of Texas Report N... [Published HispanicBusiness.com - Jul 30 2014]
Pharmacological modulation of autophagy enhance... [Published 7thSpace - Jul 30 2014]
Hospira's (HSP) CEO Michael Ball on Q2 2014 Res... [Published Seeking Alpha - Jul 30 2014]
Drug Eluting Balloons Market: New Industry Rese... [Published MyNewsDesk - Jul 30 2014]
HPV-Related Oropharyngeal Cancer: Lowered Radia... [Published Oncology Times - Jul 30 2014]
Biomineralized Anisotropic Gold Microplate–Mac... [Published ACS Applied Materials & Interfaces - Jul 30 2014]
Boston Scientific receives CE mark for agent dr... [Published Cardiovascular Business - Jul 30 2014]
Endocyte Reports Second Quarter Financial Resul... [Published Crawford Financial Planning - Jul 29 2014]
Boston Scientific Receives CE Mark For Ranger D... [Published Diagnostic & Invasive Cardiology - Jul 28 2014]
Nanotax trail shows promise in treating abdomin... [Published Noodls - Jul 28 2014]
Boston Scientific Receives CE Mark For Ranger? ... [Published Pharmacy Choice - Jul 28 2014]
The PI3K/AKT/ mTOR Pathway in Breast Cancer [Published General Medicine eJournal - Jul 28 2014]
Stent Thrombosis and New-Generation DES in Prim... [Published General Medicine eJournal - Jul 28 2014]
Genentech's ovarian cancer drug receives FDA ac... [Published Individual.com - Jul 25 2014]
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - Jul 25 2014]
AbbVie Reports Second-Quarter 2014 Financial Re... [Published Scottrade - Jul 25 2014]
Kinex receives FDA approval to begin Phase I st... [Published News-Medical.Net - Jul 25 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Oncolytics Biotech® Inc. Announces Completion o... [Published PR Newswire: Health - Jul 08 2014]
CALGARY, July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics")(TSX:ONC, NASDAQ:ONCY) today announced completion of patient enrollmentin a two-arm randomized phase II study of carboplatin, paclitaxel plusREOLYSIN® versus carboplatin and paclitaxel ...
Hanmi Pharmaceuticals and Collaborative Partner... [Published PR Newswire: Health - Jun 30 2014]
BUFFALO, N.Y. and SEOUL, South Korea, June 30, 2014 /PRNewswire/ -- Hanmi Pharmaceuticals announces a positive study on Oraxol® use in a Phase I/II clinical proof-of-concept study (Study HM-OXL-201) of Oraxol - an oral form of the approved drug paclitaxel, ...
AbbVie Announces Initiation of Pivotal Phase II... [Published PR Newswire: Health - Jun 26 2014]
NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and ...
After Chemo, What next? [Published HealthBoards - Jun 19 2014]
My wife, Lorraine (51) has recently completed 6 (3 week cycles) of (palliative) chemotherapy treatment (Paclitaxel and Carboplatin).She has an unknown primary, probably cervical but with no sign or symptoms in this area. Maybe the cancer cleared here ...
Will Gilenya stop pain [Published Multiple Sclerosis Research - Jun 06 2014]
Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, Kamocki K, Doyle T, Snider A, Esposito E, Cuzzocrea S, Bieberich E, Obeid L, Petrache I, Nicol G, Neumann WL, Salvemini D. The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires ...
1 2 3 4

Press Releases

sort by: Date | Relevance
Oasmia’s Lead Human Product Paclical® Successfu... [Published GlobeNewswire: Acquisitions News - Jun 16 2014]
Oasmia Receives FDA Conditional Approval For It... [Published GlobeNewswire: Acquisitions News - Feb 28 2014]
OncoMed Pharmaceuticals Commences Third Phase 1... [Published GlobeNewswire: Advertising News - Feb 20 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.